CRNX News and Press, Crinetics Pharmaceuticals Inc. From 09/04/20

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced t...

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below: Webcast L...

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced ...

Crinetics Pharmaceuticals ( CRNX ) has a lead molecule, paltusotine, that may be best in class. Phase 2 testing is on track to be completed in Q4 2020 and may act as a catalyst for the stock to move up if the data is positive. Peak sales potential for paltusotine, if approved, could reach $1.5...

Crinetics Pharmaceuticals (NASDAQ: CRNX ) : Q2 GAAP EPS of -$0.53 beats by $0.02 . More news on: Crinetics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolled patients in the ongoing Phase 2 ACROBAT Edge clinical trial for paltusotine had completed the study as of June and topline data is expected in fourth quarter 2020 Reported positive in...

The FDA designates Crinetics Pharmaceuticals' (NASDAQ: CRNX ) paltusotine an Orphan Drug for the treatment of acromegaly , a disorder in which the pituitary gland secretes too much growth hormone resulting in excessive bone growth, typically in the face, feet and hands. More news on: Cr...

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced th...

NOTE: MM = million Our analysis concludes Chiasma, Inc.'s (CHMA) share price is materially undervalued primarily because, at $6/share or ~$300 million market cap, CHMA trades at only slightly more than estimated peak annual revenues (just in the United States, completely excluding the rest o...

28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands (SRLs) Recruitme...